HARBIN PHARMACEUTICAL GROUP

Harbin Pharmaceutical Group Co., Ltd. (HPGC) is a state-controlled Sino-foreign equity joint venture. It is composed of domestically famous pharmaceutical companies like HPGC General Factory, HPGC Sanjing, HPGC Sixth Factory, HPGC Chinese Medicine, HPGC Bioengineering and HPGC Vaccine, and commercial circulation companies like HPGC Medicine, HPGC Sales and HPGC Marketing. HPGC has two listed companies, HPGC Holding and HPGC Sanjing. HPGC owns 45.06% equity stake in HPGC Holding, and HPGC Holding... owns 74.82% equity stake in HPGC Sanjing. HPGC has more than 20,000 employees, and total assets of 18.5 billion RMB. HPGC is integrated with pharmaceutical manufacture, trade and R&D. They have seven main business segments, which are antibiotics, small-molecular drug preparations, OTC and healthcare products, modern Chinese medicines, biopharmaceuticals, animal vaccines and medicine circulations. They produce more than 20 dosage forms and over 1000 drugs. The annual production capacity is 15 thousand tons of API and intermediates, 2 billion vials of small-molecule drug for injection, 100 million vials of Chinese medicine for injection, 180 million vials of solution injections, 11 billion tablets, 14 billion capsules, 2.2 billion vials of oral solutions and 30 billion doses of animal vaccines. HPGC products are sold throughout China and more than fifty other countries. The market shares of cephalosporin APIs and preparations, healthcare product series of calcium supplements, and Chinese medicines for injection consistently rank first in the country. Part of their products has reached European, Asian, African, and Middle and North American markets. The annual foreign exchange earning is more than 100 million dollars. More than 100 products exceed revenue of 10 million RMB, over 30 of which exceed 100 million RMB.More